Semler Scientific Inc's fundamentals are relatively stable, with low ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 111 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.67.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Semler Scientific Inc's Score
Industry at a Glance
Industry Ranking
111 / 206
Overall Ranking
253 / 4555
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Semler Scientific Inc Highlights
StrengthsRisks
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.29M.
Undervalued
The company’s latest PE is 3.65, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.05M shares, decreasing 27.59% quarter-over-quarter.
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.